Founded in 2020 by Temple University chemist Christian Schafmeister, Ladder Bio is a Blue Bell biotechnology company developing Spiroligomer™ molecules—synthetic, ladder-shaped compounds designed for targeted drug discovery. Its platform combines rational molecular design with libraries containing billions of compounds, pursuing therapeutics and diagnostic applications where conventional small molecules and biologics can fall short. Formerly known as ThirdLaw Molecular, the company has also received more than $16.9 million in non-dilutive funding from the U.S. Department of Defense and the Defense Threat Reduction Agency for biosecurity-related work.
Financial Conflicts of Interest Policy (TLM-FIN-01)
compliance_program
Kannalife Sciences, IncFounded in 2010 and based at the Pennsylvania Biotechnology Center in Doylestown, Kannalife Sciences develops patented synthetic CBD-inspired therapeutics for neuroinflammation, neuropathic pain and neurodegenerative disease. Its lead investigational molecule, KLS-13019, is being advanced as a potential non-opioid treatment for chemotherapy-induced peripheral neuropathy, with research also examining Parkinson’s disease and other conditions linked to oxidative stress. Kannalife is a wholly owned Neuropathix subsidiary whose scientific team reports more than 75 years of combined pharmaceutical research experience and over 65 jointly held patents.DOYLESTOWN, PA
Rapafusyn PharmaceuticalsEmerging from Johns Hopkins professor Jun O. Liu’s laboratory, Rapafusyn Pharmaceuticals develops non-degrading molecular-glue medicines designed to reach hard-to-drug intracellular and transmembrane targets. Based on its RapaGlue™ platform, the Baltimore biotech is advancing an early pipeline that includes an ENT1 inhibitor for acute kidney injury, an area where the company says no approved preventive therapies exist. Its discovery engine combines AI-enabled machine learning with a DNA-encoded library containing more than 8 billion non-degrading glues.BALTIMORE, MD
GeneLancet BiosciencesEstablished in November 2019, Doylestown-based GeneLancet Biosciences develops in vivo gene and cell therapies built around its proprietary single-molecule guide RNA, or LgRNA. The company is advancing LgRNA-conjugate-guided STAR and DuoSTAR genome editors for precise treatments aimed at serious diseases including neurodegenerative disorders, cancer and chronic hepatitis B. Its platform emphasizes scalable, high-purity guide RNA and editing approaches designed to avoid double-strand DNA breaks and support repeat or multiplex treatment strategies.541714DOYLESTOWN, PA
Trailhead BiosystemsFounded in 2015 as a Cleveland Clinic and Case Western Reserve University spinout, Trailhead Biosystems is a Beachwood biotechnology company built around the research of founder Jan Jensen. It is known for HD-DoE®, a data-driven platform that uses computational modeling and robotic experimentation to direct induced pluripotent stem cells into specialized human cells for researchers developing new medicines and cell therapies.BEACHWOOD, OH